SG Americas Securities LLC Makes New $893,000 Investment in Twist Bioscience Corporation (NASDAQ:TWST)

SG Americas Securities LLC purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,751 shares of the company's stock, valued at approximately $893,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TWST. Arizona State Retirement System grew its holdings in shares of Twist Bioscience by 1.3% in the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after purchasing an additional 219 shares during the last quarter. Van ECK Associates Corp boosted its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Hillsdale Investment Management Inc. boosted its position in Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after buying an additional 300 shares in the last quarter. GAMMA Investing LLC grew its stake in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C increased its holdings in shares of Twist Bioscience by 1.7% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock worth $1,107,000 after buying an additional 403 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 689 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the transaction, the insider now owns 110,849 shares in the company, valued at approximately $4,173,464.85. The trade was a 0.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction on Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the sale, the chief operating officer now owns 265,460 shares in the company, valued at approximately $10,615,745.40. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,673 shares of company stock worth $720,412. Insiders own 3.01% of the company's stock.

Analyst Upgrades and Downgrades

TWST has been the topic of several recent analyst reports. Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Barclays reduced their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Guggenheim restated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Trading Up 5.8%

Twist Bioscience stock traded up $1.97 during mid-day trading on Thursday, hitting $35.89. The stock had a trading volume of 1,072,492 shares, compared to its average volume of 974,847. The stock has a 50-day simple moving average of $33.83 and a two-hundred day simple moving average of $41.33. The company has a current ratio of 4.51, a quick ratio of 4.24 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $2.15 billion, a PE ratio of -11.04 and a beta of 2.38. Twist Bioscience Corporation has a 12 month low of $27.12 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The business had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.